Severe nonproliferative diabetic retinopathy

Summary

Severe nonproliferative diabetic retinopathy (MONDO:0004687) is a disease and 2 clinical trials. Top therapeutic interventions include conbercept. A subtype of background diabetic retinopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	severe nonproliferative diabetic retinopathy
Mondo ID	MONDO:0004687
DOID	DOID:8946
ICD-11	561966379
SNOMED CT	312905005
UMLS	C0730278
MedGen	676487
Is cancer (heuristic)	no

Also known as: severe nonproliferative diabetic retinopathy

Disease family

This is a subtype of background diabetic retinopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › diabetic retinopathy › background diabetic retinopathy › severe nonproliferative diabetic retinopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01790945	Not specified	UNKNOWN	Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
NCT03863535	Not specified	UNKNOWN	PRP vs PRP+IVC for Severe nPDR

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CONBERCEPT	3	1